Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (ixekizumab): Graviditet, fertilitet och amning

Det finns otillräckligt med data från människor för att fastslå hur säkert ixekizumab är vid graviditet.


Short Summary


There is a limited amount of data from the use of ixekizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to

  • pregnancy,
  • embryonic/foetal development,
  • parturition or
  • post-natal development.

As a precautionary measure, it is preferable to avoid the use of ixekizumab during pregnancy.1

Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment.1

Ixekizumab is a humanized IgG4 monoclonal antibody.2

  • Human IgG is known to cross the placental barrier.3,4
  • Therefore, ixekizumab may be transmitted from the mother to the developing fetus.


It is not known whether ixekizumab is excreted in human milk or absorbed systemically after ingestion. However, ixekizumab is excreted at low levels in the milk of cynomolgus monkeys.1

A decision should be made whether to discontinue breast-feeding or to discontinue ixekizumab taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.1


The effect of ixekizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.1

Information from the Clinical Trials

Limited safety data are available on the use of ixekizumab in pregnant women who are exposed to ixekizumab.5

Pregnant and breastfeeding women were excluded from ixekizumab clinical trials. Women who became pregnant were discontinued from the trials.6-11

All women agreed to use a reliable method of birth control during ixekizumab clinical trials and for at least 12 weeks following the last dose of ixekizumab.6-9,11

Pregnancy Outcomes

Psoriasis and Psoriatic Arthritis Clinical Trials

In the case of pregnancy in a study patient, her discontinuation from study treatment was required per protocol.12

Of 2499 female patients exposed to ixekizumab in 16 PsO and PsA clinical trials through September 20, 2018, 50 cases of pregnancy were identified and the outcome is known for 44 cases of pregnancy. All but 4 women were known to have been exposed to ixekizumab during their first trimester of pregnancy.12

Cumulative Summary of Pregnancies: Female Clinical Trial Participants Exposed to Ixekizumab in Psoriasis and Psoriatic Arthritis Trials12


Female Patients Exposed to Ixekizumab in RCTs

Pregnancies, n (%)

50 (2.0)

Mean age, years (±SD)

30.2 (±6.1)

Exposure during first trimester, n (%)

46 (92)

Pregnancies with known outcome,a n


Live birth,b n (%)

24 (54.5)

Spontaneous abortion, n (%)

9 (20.5)

Induced abortion, n (%)

11 (25.0)

Abbreviation: RCT = randomized controlled trial.

aNo congenital malformations were reported.

bOf the 24 live births, 18 (75.0%) were full-term, 4 (16.7%) were premature, and details were unknown for the remaining 2 (8.3%) patients.

Axial Spondyloarthritis Trials

Across all female patients enrolled in the axSpA trials (including AS/r-axSpA and nr-axSpA trials), 2 pregnancies were reported as of April 1, 2019. These 2 patients were enrolled in the COAST-X trial in patients with nr-axSpA. Both pregnancies led to term deliveries.13


1Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands

2Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. http://dx.doi.org/10.2147/JIR.S100940

3Pitcher-Wilmott RW, Hindocha P, Wood CB. The placental transfer of IgG subclasses in human pregnancy. Clin Exp Immunol. 1980;41(2):303-308. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1537014/

4Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104(1):228-233. https://journals.lww.com/ajg/Fulltext/2009/01000/Placental_Transport_of_Immunoglobulins__A_Clinical.37.aspx

5Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43-53. http://dx.doi.org/10.1016/j.jaad.2018.06.056.

6Nash P, Kirkham B, Okada M, et al; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317-2327. http://dx.doi.org/10.1016/S0140-6736(17)31429-0

7Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711

8Deodhar A, Poddubnyy D, Pacheco-Tena C, et al; COAST-W Study Group. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599-611. http://dx.doi.org/10.1002/art.40753

9van der Heijde D, Cheng-Chung Wei J, Dougados M, et al; COAST-V Study Group. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441-2451. http://dx.doi.org/10.1016/s0140-6736(18)31946-9

10Mease PJ, van der Heijde D, Ritchlin CT, et al; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. http://dx.doi.org/10.1136/annrheumdis-2016-209709

11Deodhar A, van der Heijde D, Gensler LS, et al; COAST-X Study Group. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53-64. http://dx.doi.org/10.1016/S0140-6736(19)32971-X

12Egeberg A, Kimball AB, Feldman SR, et al. Ixekizumab and pregnancy outcomes in patients with psoriasis or psoriatic arthritis. Poster presented at: 28th European Academy of Dermatology and Venereology Congress; October 9-13, 2019; Madrid, Spain.

13Data on file, Eli Lilly and Company and/or one of its subsidiaries.


AE = adverse event

AS/r-axSpA = ankylosing spondylitis/radiographic axial spondyloarthritis

axSpA = axial spondyloarthritis

IgG = immunoglobulin G

IgG4 = immunoglobulin G subclass 4

nr-axSpA = nonradiographic axial spondyloarthritis

PsA = psoriatic arthritis

PsO = psoriasis

Datum fӧr senaste ӧversyn 2020 M03 18

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss